By: Sharupa Azmal, PharmD Candidate c\/o 2026, Sarah El-Rowmeim, PharmD Candidate c\/o 2027, Akhila Ajith Kumar, PharmD Candidate c\/o 2027, & Sophia Migias, PharmD Candidate c\/o 202<\/p>\n\n\n\n
Introduction<\/strong><\/p>\n\n\n\n Real-world evidence (RWE) is defined as clinical findings regarding the use, benefits, and risks of a drug outside of traditional clinical trials.1 <\/sup>These insights are derived from real-world data (RWD), which can be collected from numerous sources, such as electronic health records (EHRs), medical claims, or product and disease registries. RWE provides a comprehensive understanding of how medical interactions function in everyday clinical settings, contrary to traditional clinical trials, which are conducted under carefully monitored conditions. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) recognize the growing significance of RWE, as shown in their Real-World Evidence Program, which strives to implement RWE into decision-making for drug approvals and safety monitoring. Under the 20th Century Cures Act, the FDA\u2019s RWE Program is required to evaluate how RWD can be used to generate RWE that demonstrates a drug\u2019s effectiveness. This can be used to support the approval of new indications or meet post-approval study requirements.2<\/sup> <\/p>\n\n\n\n The importance of RWE in healthcare is evident in areas where clinical trials present ethical barriers. One notable field is pediatric drug development, where conducting clinical trials in children raises a few ethical considerations. One of these is beneficence, which is the concept of ensuring that minors are not harmed and exploited due to their inability to provide assent. There is also justice, the idea that all individuals should have equitable access to the same benefits and risks of a drug. Many factors have an impact on justice in clinical research, such as demographic differences (gender, socioeconomic status, race), mental status, and coercion of financial incentives. In particular for the pediatric population, there is the concern that monetary rewards can convince children to provide assent to participate in a study, which can be considered a conflict of interest. Therefore, if financial incentives are provided by investigators, they are thoroughly reviewed by an Institutional Review Board (IRB) before the study can proceed. Moreover, receiving informed assent can also be challenging since it may be difficult to communicate information about the study to children, especially if they are on the younger end of the spectrum.3<\/sup> Overall, these are the determinants that limit the ability to recruit pediatric patients for clinical trials. <\/p>\n\n\n\n Relying on RWE can help fill gaps in pediatric drug research by using existing data to assess drug efficacy and safety without exposing children to unnecessary risks. Additionally, the FDA has accepted RWE to support drug product approvals, primarily in oncology and rare disease settings where randomized trials may be considered unethical. In these cases, single-arm interventional trials are used, and RWE consisting of historical response rates from medical records and expanded access programs are used to evaluate the drug\u2019s effectiveness.<\/p>\n\n\n\n Benefits and Limitations of RWE<\/strong><\/p>\n\n\n\n RWE offers several advantages that complement traditional clinical trials. For one, pediatric populations are often underrepresented in clinical research due to ethical and logistical challenges. RWE helps bridge this gap by providing data from real-world clinical use, enabling the assessment of long-term safety, rare adverse effects, and effectiveness in diverse pediatric populations, all of which are factors that may not be fully exhibited in short-term trials. Unlike traditional trials, which often have specific enrollment criteria, RWE incorporates data from a broader range of pediatric patients, including those with comorbidities or taking multiple medications. Additionally, conducting randomized controlled trials in children can be challenging, especially regarding placebo use.4<\/sup> When an effective treatment exists, assigning children to a placebo group could deny them necessary care, potentially leading to harm. RWE offers an alternative by analyzing data from routine clinical practice, reducing reliance on placebo-controlled studies while still generating valuable evidence. RWE can expedite drug approvals by supplementing traditional trial data with real-world facts, leading to quicker access to essential medications for children. Since pediatric drug dosing is often decided from adult data, RWE helps refine dosing recommendations based on actual clinical use, ensuring safer and more effective treatment regimens. It also supports improvements in packaging instructions and manufacturer labeling to better align with pediatric needs.<\/p>\n\n\n\n Although real-world evidence offers valuable information, certain limitations can interfere with its effectiveness. RWE is often derived from electronic health records, insurance claims, and patient registries, which may contain missing, incomplete, or inaccurate data, leading to inconsistencies. Unlike randomized controlled trials, which follow strict protocols, RWE comes from uncontrolled environments, making decision-making more challenging. Additionally, variations in data collection across different clinical settings can create organizational issues and reduce data reliability. Pediatric drug dosing requires precise weight- and age-based adjustments, but RWE may lack the precision needed for accurate pediatric dosing adjustments.5<\/sup> Variations in off-label use make it harder to understand how dosage affects response, which complicates setting proper treatment guidelines. <\/p>\n\n\n\n A Pediatric Drug Approval<\/strong> Based On RWE<\/strong><\/p>\n\n\n\n An example of RWE being successful includes the FDA’s approval of Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. cGVHD is a life-threatening condition that occurs after patients receive a hematopoietic stem cell transplantation and the donor cells attack healthy organs and tissues in the body. This impacts multiple organs such as the skin, eyes, mouth, and lungs. Typically, patients experiencing cGVHD are provided with corticosteroid therapy. However, in this study there was a single-arm trial of 42 patients with persistent cGVHD despite receiving corticosteroid treatment. They tested the efficacy and safety of Imbruvica on these patients and the trial showed a 67% response rate, with symptom improvement lasting five months or longer in nearly half of the patients. As a result, the FDA decided to expand the approval of Imbruvica to include patients with cGVHD based on these findings. This study demonstrates how incorporating real world evidence as clinical data was able to expedite approval and provide treatment options for patients with limited alternatives.7<\/sup><\/p>\n\n\n\n Conclusion<\/strong><\/p>\n\n\n\n Overall, pediatric drug development has been able to make meaningful progress due to the utilization of RWE. Many studies leveraging RWE that are submitted for regulatory review are for new drug indications or product label expansion. From 2016 and 2022 alone, a large proportion of RWE based approvals were concentrated in oncology, a therapeutic area that is characterized by significant gaps in clinical care. While RWE has played a critical role in increasing access to lifesaving medications for pediatric patients, there are still improvements that need to be made regarding the quality and utility of these studies. Moving forward, it is essential that continued efforts are made to standardize RWE methodologies while ensuring that children can benefit from novel therapies.3<\/sup> <\/p>\n\n\n\n References<\/strong><\/p>\n\n\n\n By: Sharupa Azmal, PharmD Candidate c\/o 2026, Sarah El-Rowmeim, PharmD Candidate c\/o 2027, Akhila Ajith Kumar, PharmD Candidate c\/o 2027, & Sophia Migias, PharmD Candidate c\/o 202 Introduction Real-world evidence (RWE) is defined as clinical findings regarding the use, benefits, and risks of a drug outside of traditional clinical trials.1 These insights are derived from…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,4],"tags":[],"class_list":["post-4128","post","type-post","status-publish","format-standard","hentry","category-clinical","category-featured"],"views":62,"_links":{"self":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/comments?post=4128"}],"version-history":[{"count":1,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4128\/revisions"}],"predecessor-version":[{"id":4129,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4128\/revisions\/4129"}],"wp:attachment":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/media?parent=4128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/categories?post=4128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/tags?post=4128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n